Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Cancers|November 12, 2013
Neuropilins: a new target for cancer therapyCamille Grandclement, Christophe Borg
Vaccines|September 10, 2015
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineJeanne Galaine, Christophe Borg, Yann Godet, et al.
Oncoimmunology|December 25, 2012
Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?Yann Godet, Magalie Dosset, Christophe Borg, et al.
Bulletin Du Cancer|January 29, 2019
Marie-Thérèse Rubio, Jeanne Galaine, Christophe Borg, et al.
Therapeutic Advances in Medical Oncology|September 16, 2024
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected responseClémentine Daugan, Romain Boidot, François Ghiringhelli, et al.
Bulletin Du Cancer|January 11, 2021
[Squamous cell anal carcinoma. What's next ?]Stefano Kim, Laurie Spehner, Luc Cabel, et al.
International Journal of Molecular Medicine|January 19, 2017
DNA damage response defect in Williams-Beuren syndromeDavid Guenat, Giuseppe Merla, Eric Deconinck, et al.
Bulletin Du Cancer|July 2, 2026
[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté]Jeanne Longet, Antonia Altmeyer-Figuière, Quentin Jacquinot, et al.
Bulletin Du Cancer|August 3, 2015
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]Marine Jary, Christophe Borg, Olivier Bouché, et al.
Human Vaccines & Immunotherapeutics|January 30, 2013
Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccineOlivier Adotévi, Magalie Dosset, Jeanne Galaine, et al.
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Cancers|November 12, 2013
Neuropilins: a new target for cancer therapyCamille Grandclement, Christophe Borg
Vaccines|September 10, 2015
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineJeanne Galaine, Christophe Borg, Yann Godet, et al.
Oncoimmunology|December 25, 2012
Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?Yann Godet, Magalie Dosset, Christophe Borg, et al.
Bulletin Du Cancer|January 29, 2019
Marie-Thérèse Rubio, Jeanne Galaine, Christophe Borg, et al.
Therapeutic Advances in Medical Oncology|September 16, 2024
Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected responseClémentine Daugan, Romain Boidot, François Ghiringhelli, et al.
Bulletin Du Cancer|January 11, 2021
[Squamous cell anal carcinoma. What's next ?]Stefano Kim, Laurie Spehner, Luc Cabel, et al.
International Journal of Molecular Medicine|January 19, 2017
DNA damage response defect in Williams-Beuren syndromeDavid Guenat, Giuseppe Merla, Eric Deconinck, et al.
Bulletin Du Cancer|July 2, 2026
[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté]Jeanne Longet, Antonia Altmeyer-Figuière, Quentin Jacquinot, et al.
Bulletin Du Cancer|August 3, 2015
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?]Marine Jary, Christophe Borg, Olivier Bouché, et al.
Human Vaccines & Immunotherapeutics|January 30, 2013
Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccineOlivier Adotévi, Magalie Dosset, Jeanne Galaine, et al.
Pageof 23